Social Media Learning Series
First-Line Focus: BRAF-Driven Treatment Decision
Welcome to a new #accredited #tweetorial on #BRAFTargetedTherapy.
This tweetorial provides 0.25 AMA PRA Category 1 Credits. #CME.
Statement of accreditation and disclosures can be found here.
This program has been supported by an independent medical education grant from Pfizer and is delivered in joint providership with CCI.
So . . .
How much do you know about #BRAFTargetedTherapy in #mCRC and #NSCLC? 🤔
Personalizing First-Line Therapy
⚕️#BRAFV600E #mCRC has a poor prognosis phenotype that deserves adequate and specific treatment. But how is BRAF clinically relevant?
✔️ Usually right sided
✔️ Presents with large mass
✔️ Poorly differentiated histology
✔️ dMMR 15-20% of the time
✔️Main class is V600E
🏥 #BREAKWATERmCRC #OverallSurvival
🗓️ Interim OS
✔️ Median OS: 30 months with EC + mFOLFOX6; 15 months with SoC
🤝🏻 OS doubled; results led to #1L #FDAApproval
Staying Ahead of AEs
🔎Now let’s explore adverse events with #BRAFTargetedTherapy in #mCRC
✔️ In the #BREAKWATERmCRC trial:
⬆️ Increased anemia, vomiting, arthralgia, asthenia, pyrexia, rash with EC + FOLFOX6 🆚 chemotherapy
✔️ Rash mostly grade 1 and 2
👍EC + FOLFOX6 well tolerated overall
❓What about adverse events with #BRAFTargetedTherapy in #NSCLC?
✔️ In the #PHAROS trial:
✔️ Safety profile as expected with #encorafenib plus #binimetinib
✔️ Some rash (10%)
✔️ Most grade 3–4 toxicities ➡️ gastrointestinal
Biomarkers in Practice
#BRAFTargetedTherapy in #2L #mCRC
✔️ Phase 3 BEACON trial
✔️ Patients progressed on frontline chemotherapy
✔️ Primary endpoint was met: significant benefit for #encorafenib + #cetuximab 🆚 control
🤝🏻 Results led to #2L #FDAApproval
✔️ #ASCO, #ESMO and #NCCN guidelines changed
💉 Should #ImmuneCheckpointInhibitors be added in patients with MSI-high #BRAFV600E tumors?
✔️ #KEYNOTE177 - #ImmuneCheckpointInhibitor
✔️ BRAF-mutated #mCRC benefitted from #ImmuneCheckpointInhibitor
❓ What about sequencing?
🔂Start with ICI ➡️ switch to #encorafenib + #cetuximab in #2L ➡️ chemotherapy in later lines
Thank you for participating in this tweetorial! We hope you are as excited about the future of #BRAFTargetedTherapy as we are!
Claim your FREE credit NOW here and follow us for more CE/#CME!